Business Wire

Planview Continues Acceleration with Record Revenue in FY’22

30.1.2023 17:00:00 EET | Business Wire | Press release

Share

Planview, the leading platform for connected work from portfolio planning to delivery, today announced record annual recurring revenue (ARR) for fiscal year 2022, continuing a trend of strong performance. Planview exceeded $380 million in total ARR for 2022, representing 17% growth year-over-year (YoY).

“It was another record year for Planview, underpinned by our commitment to build the digital future of connected work through product innovation and customer success,” said Razat Gaurav, Chief Executive Officer, Planview. “The macroeconomic uncertainties and headwinds faced by organizations today make prioritizing product and project initiatives, and thoughtfully allocating constrained resources and capital, more important than ever. Our global customer base relies on our solutions to help them achieve productivity, efficiency, and positive business outcomes from transformation initiatives across the enterprise.”

Fiscal Year-End Highlights

Planview achieved record levels for the full fiscal year 2022:

  • Total revenue surpassed $410 million for the full year
  • ARR grew by over 17% YoY to over $380M
  • Record 25% increase in monthly active users YoY for leading products
  • Customer retention rates are up 6% YoY

Strong New Logo and Customer Momentum Driven by Product Innovation

Key customer wins and expansions have driven Planview’s profitable growth. In 2022, the company added 482 net new customers. New and notable customers who selected or expanded their footprint with Planview include: Builders FirstSource, Inc., Delta Dental of California, DS Smith, Fonterra, General Motors, Maximus, Inc., Olam International Limited, Publicis, RxBenefits, Schluter, Siemens, Sysco Corporation, T-Mobile, The Emmes Company, LLC, Tetra Pak, and UiPath.

This growth was accelerated by the success of Planview’s connected platform of solutions, which helps organizations improve time-to-value, do more with the teams and resources allocated, and de-risk strategic investment decisions. Planview’s innovation over the past year continued to drive desired business outcomes for customers. Enhancements include:

  • Expanding Objective and Key Results (OKRs) capabilities, enabling access to an embedded goal framework across the enterprise
  • Introducing Time-to-Market dependency and outlier analytics, ensuring organizations can focus their investments and resources where they are most needed
  • Extending visual planning and prioritization support and card automation capabilities, centrally defining planning and delivery increments and streamline productivity across multiple teams
  • Enhancing UX/UI functionality

Additionally, the strategic acquisitions of Tasktop and Enrich in the first half of 2022 fueled Planview’s data science, planning, connectivity, and transformation offering. The Value Stream Management solution added last year, via the Tasktop acquisition, empowers organizations to accelerate their time to market, improve operational efficiency, and drive investment confidence in the face of economic disruption and instability.

Leading industry analyst firms have named Planview a leader in several key reports last year, reinforcing Planview’s leadership in Strategic Portfolio Management (SPM), Enterprise Agile Planning (EAP), Project and Portfolio Management (PPM), and Value Stream Management (VSM). Reports include:

Investing in Customer Success

To support continued customer success, training and learning were areas of strategic focus and investment. The company expanded a dedicated global learning team responsible for driving the Planview instructor-led training programs, developing new, engaging e-Learning offerings, and deploying a flagship learning management system, The University of Planview. The company also expanded its Evolve Advisory Services, supporting customers with the people and process change management that is required as part of business transformation.

To help deliver successful solutions to customers across the globe, faster, Planview also expanded its partner ecosystem, including new or expanded strategic relationships with the likes of Accenture, Atos, AWS, Deloitte, Infosys, and PwC, among others.

Planview Expands to Support Global Customer-base

Offering additional support for a more global customer base, Planview made strategic hires across its product development, customer success, sales, and marketing functions. Scaling up the company’s global operations, Planview opened a new regional office in Singapore and invested heavily in growing the company’s Global Capacity & Innovation Center in Bangalore, increasing its headcount in APAC by 65%.

To learn more about Planview, visit: www.planview.com.

About Planview

Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com

About Business Wire

Business Wire
Business Wire



http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye